'It just needs to be better studied': FDA advisory committee rejects MDMA for PTSD

An FDA advisory committee voted against recommending a psychedelic treatment for PTSD, citing insufficient data for what many described as a still-promising path forward.The Psychopharmacologic Drugs Advisory Committee met June 4 to discuss a new drug application for midomafetamine (MDMA) — submitted by Lykos Therapeutics, formerly MAPS Public Benefit Corporation. It was the first FDA

Related Keywords

Stephanie Viguers ,Elizabeth Joniak ,David Millis ,Byemma Bascom ,Maryann Amirshahi ,Public Benefit Corporation ,University Of North Carolina ,Meeting Of The Psychopharmacologic Drugs Advisory Committee ,Georgetown University School Of Medicine ,Chapel Hill Injury Prevention Research Center ,National Capital Poison Center ,Psychopharmacologic Drugs Advisory Committee ,Lykos Therapeutics ,North Carolina ,Chapel Hill ,Injury Prevention Research Center ,Georgetown University School ,Psychopharmacologic Drugs Advisory ,Accessed June ,